Q-omics provides the consensus-scored FAN1 profile across patient tissues and cancer cell-line models. FAN1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAN1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FAN1 RNA expression shows 21,239 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where FAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAN1 survival associations across molecular data types. FAN1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAN1 RNA expression–survival associations across cancer types. High FAN1 expression shows unfavorable associations in BLCA, MESO, LUSC and COAD, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAN1 RNA expression.
This table summarizes FAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAN1 shows lower tumor expression in THCA, KIRC and BRCA and higher tumor expression in COAD, LIHC and LUSC. The THCA box plot shows higher FAN1 RNA expression in normal versus tumor tissue (log2 FC = −1.002, t-test p < 0.001).
This table shows molecular features associated with FAN1 in patient tissues and cancer cell lines. In patient samples, FAN1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
